Wuxi Shuangliang Biotechnology Co., Ltd.

Chengchen Wang

Jiaquan Wu

Shuai Zhang

Zhenghua Lu

Jian Dong

Huanyan Cao

Teng Wang

Shenshuang Jin

Haijun Zhang

Qiu Tan

Feng Fan

Jie Zhang

Xiaoyi Ji

Minqi Gao

The present disclosure discloses a compound as represented by formula (I) or a pharmaceutically acceptable salt, a solvate or a stereoisomer thereof, that can be represented by the following structure  As a selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), the compounds of the present disclosure may be used for treating or preventing a disease at least partially modulated by CDK4/6.

Selective CDK4/6 inhibitor and preparation thereof

The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exonl9 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives.

2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof

Growing community of inventors

Jiangyin, China

Chengchen Wang